PTCH1 and cutaneous squamous cell carcinoma: In humans, these inhibitors can lead to the development of BCC-adjacent cSCC (cutaneous squamous cell carcinoma) [24,25,26], which show decreased Hh/Ptch but increased Ras/MAPK signaling [27].